“We are committed to investing in state-of-the-art technologies that advance the most effective preclinical science for our Sponsors” – Peter M. Markham, President and CEO, CBSET
LEXINGTON, Mass., November 19, 2013 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, has expanded its preclinical development capabilities with the installation of an Innova• Image Guided System 520 from GE Healthcare for interventional cardiology, cardiovascular surgery, and electrophysiology research applications. CBSET is the only non-for-profit, preclinical-focused organization in the worldwide life sciences industry that offers this advanced technology for research purposes.
Among several important features, the Innova IGS 520 Cardiovascular and Hybrid OR Imaging System includes fast-spin rotational angiography as well as 3D imaging of internal structures and devices in one image. The Innova IGS 520 can provide tissue reconstruction based on imaging of bone, soft tissues, and other internal body structures. This system allows fusion of real-time fluoroscopy with 3D anatomy from images generated during the procedure and enables visualization of blood flow in a 3D anatomical setting. This new technology provides more precise positioning of devices and visualization of devices within the anatomy. This state-of-the-art technology is revolutionizing the protocol for complicated cardiac interventions, such as the treatment of aortic or mitral valve replacement/repair procedures, AAA stent graft placement and coronary bifurcation lesions, among others. This new technology further allows combination of rotational angiography with electrophysiology imaging from EP Vision and Heart Vision, which supports localization and positioning of guidewires, ablation catheters, and other devices.
“We have an unrivaled biomedical facility to advance cutting-edge preclinical science. The addition of the world’s most sophisticated 3D imaging capability is in keeping with our mission to provide all of the services needed for the preclinical development of a medical device or drug within a single organization,” said Peter Markham, president, CEO and a co-founder of CBSET. “Since our founding in 2006, we have helped more than 350 companies attain the highest standards of excellence in preclinical science among a broad array of disciplines and domains. Such an entity did not exist, especially under one roof, prior to CBSET.”
To learn more about the services provided by CBSET, contact Dr. Erica Smith, Director of Business Development at CBSET: +1-781-296-5319, firstname.lastname@example.org.
CBSET Inc. — 500 Shire Way, Lexington, MA 02421 — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products.